Evidence map›Paper›PMID 32744322›Full record

ArticleHuman molecular genetics2020

Skeletal muscle regeneration in facioscapulohumeral muscular dystrophy is correlated with pathological severity.

Christopher R S Banerji, Don Henderson, Rabi N Tawil, Peter S Zammit

Open access · hybridAbstract read
In one paragraph

Article in Human molecular genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Christopher R S BanerjiRandall Centre for Cell and Molecular Biophysics, King's College London, London SE1 1UL, UK.
Don HendersonNeuromuscular Pathology Laboratory, Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Rabi N TawilNeuromuscular Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Peter S ZammitRandall Centre for Cell and Molecular Biophysics, King's College London, London SE1 1UL, UK.
King's College London · GBUniversity of Rochester Medical Center · US

Funding

The Pathogenesis of Facioscapulohumeral Muscular DystrophyP01NS069539 · NINDS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TAWIL, RABI · 2010 to 2019
$12.3M
Medical Research Council MR/P023215/1Medical Research Council MR/S002472/1NINDS NIH HHS P01 NS069539
6 · The paper itself

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal-dominant myopathy characterized by slowly progressive skeletal muscle weakness and wasting. While a regenerative response is often provoked in many muscular dystrophies, little is known about whether a regenerative response is regularly elicited in FSHD muscle, prompting this study. For comparison, we also examined the similarly slowly progressing myotonic dystrophy type 2 (DM2). To first investigate regeneration at the transcriptomic level, we used the 200 human gene Hallmark Myogenesis list. This myogenesis biomarker was elevated in FSHD and control healthy myotubes compared to their myoblast counterparts, so is higher in myogenic differentiation. The myogenesis biomarker was also elevated in muscle biopsies from most independent FSHD, DM2 or Duchenne muscular dystrophy (DMD) studies compared to control biopsies, and on meta-analysis for each condition. In addition, the myogenesis biomarker was a robust binary discriminator of FSHD, DM2 and DMD from controls. We also analysed muscle regeneration at the protein level by immunolabelling muscle biopsies for developmental myosin heavy chain. Such immunolabelling revealed one or more regenerating myofibres in 76% of FSHD muscle biopsies from quadriceps and 91% from tibialis anterior. The mean proportion of regenerating myofibres per quadriceps biopsy was 0.48%, significantly less than 1.72% in the tibialis anterior. All DM2 muscle biopsies contained regenerating myofibres, with a mean of 1.24% per biopsy. Muscle regeneration in FSHD was correlated with the pathological hallmarks of fibre size variation, central nucleation, fibrosis and necrosis/regeneration/inflammation. In summary, the regenerative response in FSHD muscle biopsies correlates with the severity of pathology.

Indexed as

AdultAgedBiomarkersFemaleHumansMaleMiddle AgedMuscle DevelopmentMuscle Fibers, SkeletalMuscle, SkeletalMuscular Dystrophy, DuchenneMuscular Dystrophy, FacioscapulohumeralMyoblastsMyosin Heavy ChainsMyotonic DystrophyRegenerationBiomarkersMyosin Heavy Chains

Identifiers

PMID32744322
PMCPMC7530526
OpenAlexW3047071400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.